Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- DAWN
- Price
- 6.32
- Stock movement up
- +0.17 (2.50%)
- Company name
- Day One Biopharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 714.98M
- Ent value
- 337.55M
- Price/Sales
- 6.97
- Price/Book
- 1.29
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -50.46%
- 3 year return
- -33.97%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
DAWN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.97 |
| Price to Book | 1.29 |
| EV to Sales | 3.29 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 102.43M |
| EPS (TTM) | -0.87 |
| FCF per share (TTM) | -1.67 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 102.51M |
| Gross profit (TTM) | 99.82M |
| Operating income (TTM) | -211.45M |
| Net income (TTM) | -84.29M |
| EPS (TTM) | -0.87 |
| EPS (1y forward) | -0.75 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 97.37% |
| Operating margin (TTM) | -206.27% |
| Profit margin (TTM) | -82.23% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 422.76M |
| Net receivables | 8.70M |
| Total current assets | 581.00M |
| Goodwill | 0.00 |
| Intangible assets | 16.22M |
| Property, plant and equipment | 3.48M |
| Total assets | 600.81M |
| Accounts payable | 3.02M |
| Short/Current long term debt | 2.62M |
| Total current liabilities | 39.74M |
| Total liabilities | 45.34M |
| Shareholder's equity | 555.46M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -89.48M |
| Capital expenditures (TTM) | 72.86M |
| Free cash flow (TTM) | -162.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -15.18% |
| Return on Assets | -14.03% |
| Return on Invested Capital | -15.17% |
| Cash Return on Invested Capital | -29.22% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.76 |
| Daily high | 7.00 |
| Daily low | 6.74 |
| Daily Volume | 684K |
| All-time high | 27.92 |
| 1y analyst estimate | 24.25 |
| Beta | -1.27 |
| EPS (TTM) | -0.87 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 10 Nov 2025 |
Downside potential
Loading...
Downside potential data
| DAWN | S&P500 | |
| Current price drop from All-time high | -75.00% | -1.46% |
| Highest price drop | -79.51% | -56.47% |
| Date of highest drop | 27 May 2022 | 9 Mar 2009 |
| Avg drop from high | -45.40% | -10.99% |
| Avg time to new high | 82 days | 12 days |
| Max time to new high | 997 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
714.98M
Marketcap category
Small-cap
Description
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Employees
182
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page